- Home
- TNGX vs GUG Comparison
TNGX vs GUG Comparison
Compare TNGX & GUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- GUG
- Stock Information
- Founded
- TNGX 2014
- GUG 2021
- Country
- TNGX United States
- GUG United States
- Employees
- TNGX N/A
- GUG N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- GUG Trusts Except Educational Religious and Charitable
- Sector
- TNGX Health Care
- GUG Finance
- Exchange
- TNGX Nasdaq
- GUG Nasdaq
- Market Cap
- TNGX 413.6M
- GUG 490.4M
- IPO Year
- TNGX N/A
- GUG N/A
- Fundamental
- Price
- TNGX $3.13
- GUG $14.96
- Analyst Decision
- TNGX Strong Buy
- GUG
- Analyst Count
- TNGX 8
- GUG 0
- Target Price
- TNGX $13.14
- GUG N/A
- AVG Volume (30 Days)
- TNGX 1.4M
- GUG 108.9K
- Earning Date
- TNGX 11-06-2024
- GUG 01-01-0001
- Dividend Yield
- TNGX N/A
- GUG 9.67%
- EPS Growth
- TNGX N/A
- GUG N/A
- EPS
- TNGX N/A
- GUG N/A
- Revenue
- TNGX $43,383,000.00
- GUG N/A
- Revenue This Year
- TNGX $27.73
- GUG N/A
- Revenue Next Year
- TNGX N/A
- GUG N/A
- P/E Ratio
- TNGX N/A
- GUG N/A
- Revenue Growth
- TNGX 15.67
- GUG N/A
- 52 Week Low
- TNGX $2.70
- GUG $12.71
- 52 Week High
- TNGX $13.01
- GUG $15.06
- Technical
- Relative Strength Index (RSI)
- TNGX 42.05
- GUG 34.09
- Support Level
- TNGX $2.95
- GUG $14.78
- Resistance Level
- TNGX $3.20
- GUG $15.27
- Average True Range (ATR)
- TNGX 0.27
- GUG 0.25
- MACD
- TNGX 0.08
- GUG -0.02
- Stochastic Oscillator
- TNGX 72.88
- GUG 18.63
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
About GUG Guggenheim Active Allocation Fund of Beneficial Interest
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.